A phase I clinical trial to assess the safety and tolerability of NMT-cP12 in healthy volunteers

Trial Profile

A phase I clinical trial to assess the safety and tolerability of NMT-cP12 in healthy volunteers

Planning
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs NMT-cP12 (Primary)
  • Indications Burns
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Nov 2017 New trial record
    • 31 Oct 2017 According to a NeoMatrix Therapeutics media release, the Investigational New Drug Application (IND) filed by the company for NMT-cP12 has gone into effect per the U.S. Food and Drug Administration (FDA) and the company plans to initiate this trial as soon as possible.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top